Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program-Reference-Cited by-同舟云学术

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program

Published:2021-02-02 Issue:5 Volume:44 Page:515-530
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Conaghan Philip G.^ORCID,Mysler Eduardo,Tanaka Yoshiya^ORCID,Da Silva-Tillmann Barbara,Shaw Tim,Liu John,Ferguson Ryan,Enejosa Jeffrey V.,Cohen Stanley^ORCID,Nash Peter,Rigby William^ORCID,Burmester Gerd^ORCID

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-020-01036-w.pdf

Reference76 articles.

1. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.

2. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–37.

3. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182–8.

4. Yamanaka H, Sugiyama N, Inoue E, et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2013;24:33–40.

5. Sengul I, Akcay-Yalbuzdag S, Ince B, et al. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis. Int J Rheum Dis. 2015;18:640–5.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study;Clinical Rheumatology;2024-07-02

2. Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis;Expert Opinion on Drug Metabolism & Toxicology;2024-06-26

3. Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis;Ocular Immunology and Inflammation;2024-05-06

4. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials;Advances in Therapy;2024-01-02

5. Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy;Saudi Journal of Gastroenterology;2023-12-15